Safety, Pharmacokinetics, and Food Effect of the RORα Agonist TB-840, a Novel Candidate for Metabolic dysfunction-associated steatohepatitis (MASH): A Randomized First-in-Human Study in Healthy Volunteers. Life 2025
Immune Landscape Changes in MASLD and the Effects of 11β-HSD1 Inhibition Revealed by Single-Cell Mass Cytometry. Proteomics Clinical Applications 2025
Evaluating the Association between Migraine Treatments and Tinnitus: Insights from the US Food and Drug Administration Adverse Event Reporting System. PLOS ONE 2025
Comparison of Sarcopenia Screening Indices Using Serum Creatinine and Cystatin C in Metabolic Dysfunction-Associated Steatotic Liver Disease. Frontiers in Medicine 2025
Identifying Signals of Disproportionate Reporting for Calcitonin Gene-Related Peptide Inhibitors: Real-World Evidence from the FDA Adverse Event Reporting System. Expert Opinion On Drug Safety 2025
Impact of Sirolimus on Long‐Term Adverse Cardiovascular Outcomes in Kidney Transplant Recipients: A Nationwide Cohort Study. European Journal of Clinical Investigation 2025
A Novel 11β-HSD1 Inhibitor Ameliorates Liver Fibrosis by Inhibiting the Notch Signaling Pathway and Increasing NK Cell Population. Archives of Pharmacal Research 2025
Disproportionality Analysis of Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide Inhibitors Using the Food and Drug Administration Adverse Event Reporting System. Scientific Reports 2025
Navigating Recent Changes in Dosing Information: Dynamics of FDA-Approved Monoclonal Antibodies in Post-Marketing Realities. Clinical and Translational Science 2024
Multi-Modal Fusion-based Lightweight Model for Enhanced Generalization in Drug-Target Interaction Prediction. Journal of Chemical Information and Modeling 2024.
Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight. Clinical Pharmacology & Therapeutics 2024.
Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times. Drug Design, Development and Therapy 2024.
DLM-DTI: a dual language model for the prediction of drug-target interaction with hint-based learning. Journal of Cheminformatics 2024.
Editorial: Liver hypercortisolism as a potential target for MASH treatment—Authors' reply. Alimentary Pharmacology & Therapeutics 2023.
First in Human Randomized Trial of J2H-1702: a Novel 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor for Nonalcoholic Steatohepatitis Treatment. Alimentary Pharmacology & Therapeutics 2023.
The drug-like molecule pre-training strategy for drug discovery. IEEE Access 2023.
Synthesis of Protected 1,4-trans-1,5-cis-4,5-Diamino-2-cyclopenten-1-ol via Stereoselective Vinylation of a-Amino Aldimine. Tetrahedron Letters 2023.
ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model. Life 2022, 13.
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. Br J Clin Pharmacol 2022.
Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects. Br J Clin Pharmacol 2022.
Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease. Life, 2022, 12(11), 1682.
Mass cytometry study on hepatic fibrosis and its drug induced recovery using mouse peripheral blood mononuclear cells. Frontiers in Immunology 2022, 13.
Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients. Journal of Personalized Medicine 2022, 12(2), 163.
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. Clin Transl Sci 2021.
Pharmacokinetics of Ginsenoside Compound K From a Compound K Fermentation Product, CK-30, and From Red Ginseng Extract in Healthy Korean Subjects. Clin Pharmacol Drug Dev 2021.
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease. Life 2021, 11, 250.
Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. J Affect Disord 2021, 285:120-126.
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects. Drug Des Devel Ther 2020, 14, 4493 -4502, doi:10.2147/DDDT.S275336.
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects. Drug Des Devel Ther 2020, 14, 5179 -5187, doi:10.2147/DDDT.S275343.
Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors. Pharmacol Res Perspect 2020, 8, e00568, doi:10.1002/prp2.568.
Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep 2019, 9, 19410, doi:10.1038/s41598-019-55562-4.
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharm Drug Dispos 2019, 40, 135-150, doi:10.1002/bdd.2178.
A Personalized CYP2C19 Phenotype -Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis. J Clin Med 2019, 8, doi:10.3390/jcm8020227.
Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment. Transl Clin Pharmacol 2019, 27, 107-114, doi:10.12793/tcp.2019.27.3.107.
A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers. Eur J Clin Pharmacol 2018, 74, 1605 -1613, doi:10.1007/s00228-018-2543-0.
Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. Clin Ther 2017, 39, 1849-1857, doi:10.1016/j.clinthera.2017.08.002.
Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers. Int J Clin Pharmacol Ther 2017, 55, 102 -108, doi:10.5414/CP202707.